VALN
Valneva SE
NASDAQ · Healthcare · Biotechnology · FR
$6.89
−2.41%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.9x
Market Cap
$653.33M
MomentumView details →
1D Return
−2.41%
YTD Return
−20.75%
RSI (14)
65.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.9x
Market Cap
$653.33M
RSI (14)
65.4
MomentumView details →
1D Return
−2.41%
YTD Return
−20.75%
SummaryUpdated Jun 1, 2026
Valneva SE (NASDAQ:VALN) is a French specialty vaccine company founded in 1998 and headquartered in Saint-Herblain, France. The company went public on NASDAQ in May 2021, having previously traded on European exchanges. Valneva focuses on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs, particularly targeting travel-related and emerging infectious diseases. The company has evolved from a pure research and development organization into a commercial-stage biotechnology company with marketed products and a robust pipeline of vaccine candidates in various stages of clinical development.
Similar companies
Latest newsMore news →
The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.22d agoValneva SE implemented a restructuring program, with positive effects on income statement and cash flow expected in the second half of 2026.23d agoValneva SE reported its condensed consolidated financial results for the first half of 2026, provided corporate updates, and reaffirmed its financial guidance for 2026.23d ago